Adage Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $42.9M | Buy |
+341,578
| New | +$42.9M | 0.07% | 270 |
|
|
2022
Q3 | – | Sell |
-105,000
| Closed | -$10.2M | – | 1091 |
|
|
2022
Q2 | $10.2M | Buy |
105,000
+20,000
| +24% | +$1.95M | 0.02% | 663 |
|
|
2022
Q1 | $7.97M | Sell |
85,000
-352,000
| -81% | -$33M | 0.02% | 755 |
|
|
2021
Q4 | $37.2M | Buy |
+437,000
| New | +$37.2M | 0.07% | 298 |
|
|
2019
Q4 | – | Sell |
-62,000
| Closed | -$5.59M | – | 748 |
|
|
2019
Q3 | $5.59M | Buy |
+62,000
| New | +$5.59M | 0.01% | 618 |
|
|
2019
Q1 | – | Sell |
-8,000
| Closed | -$571K | – | 723 |
|
|
2018
Q4 | $571K | Sell |
8,000
-18,000
| -69% | -$1.28M | ﹤0.01% | 689 |
|
|
2018
Q3 | $3.2M | Sell |
26,000
-126,000
| -83% | -$15.5M | 0.01% | 661 |
|
|
2018
Q2 | $14.9M | Buy |
+152,000
| New | +$14.9M | 0.03% | 478 |
|
|
2014
Q2 | – | Sell |
-136,286
| Closed | -$2.19M | – | 725 |
|
|
2014
Q1 | $2.19M | Buy |
+136,286
| New | +$2.19M | 0.01% | 640 |
|